A Phase III Trial to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
This study has been completed.
Study NCT00421928
Information provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
First Received: January 12, 2007
Last Updated: May 28, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
